Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alligator Bioscience AB's quarterly market cap
declined
from Sep. 2025 (kr201.54 Mil) to Dec. 2025 (kr167.56 Mil) and
declined
from Dec. 2025 (kr167.56 Mil) to Mar. 2026 (kr108.91 Mil).
Alligator Bioscience AB's annual market cap
declined
from Dec. 2023 (kr453.33 Mil) to Dec. 2024 (kr189.17 Mil) and
declined
from Dec. 2024 (kr189.17 Mil) to Dec. 2025 (kr167.56 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Alligator Bioscience AB's Enterprise Value for Today is kr112.46 Mil.
Alligator Bioscience AB (OSTO:ATORX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Alligator Bioscience AB Market Cap Related Terms
Alligator Bioscience AB Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ATORX vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Alligator Bioscience AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alligator Bioscience AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Alligator Bioscience AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Alligator Bioscience AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alligator Bioscience AB (OSTO:ATORX) has a Market Cap of kr113.06 Mil as of Jul. 14, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Alligator Bioscience AB and its competitors. According to the industry distribution chart, Alligator Bioscience AB ranks #1190 out of 1423 companies in the Biotechnology industry, placing it in the top 83.6%.
Is Alligator Bioscience AB's Market Cap too high?
Alligator Bioscience AB's current Market Cap is kr113.06 Mil. Based on the distribution chart, Alligator Bioscience AB ranks #1190 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alligator Bioscience AB has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alligator Bioscience AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alligator Bioscience AB ranks #1190 out of 1423 companies for Market Cap. This places Alligator Bioscience AB in the lower half of its industry. The industry median Market Cap is 115.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 115.88, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Alligator Bioscience AB and its competitors. For the Biotechnology industry, the median Market Cap is 115.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alligator Bioscience AB's current Market Cap is kr113.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Alligator Bioscience AB (OSTO:ATORX) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.01, compared to a current price of kr0.18 — trading 1700% above its estimated fair value. The current Market Cap is kr113.06 Mil. Alligator Bioscience AB's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Alligator Bioscience AB (OSTO:ATORX), the current Market Cap is kr113.06 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alligator Bioscience AB (OSTO:ATORX) Overvalued in 2026?
Based on GuruFocus' analysis, Alligator Bioscience AB stock appears to be overvalued.
The current stock price of kr0.18 is trading 1700% above its estimated GF Value™ of kr0.01.
GuruFocus considers Alligator Bioscience AB to be Significantly Overvalued.
Key valuation signals for OSTO:ATORX:
Market Cap: kr113.06 Mil
GF Value™: kr0.01 vs. price of kr0.18 (1700% above fair value)
No single metric tells the full story. See the OSTO:ATORX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
39GF Score
Get the complete analysis for OSTO:ATORX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ATORX has been successfully added to your 
